BACKGROUND: Lymph node counts are a measure of quality assurance and are associated with prognosis for numerous malignancies. To date, investigations of lymph node counts in testis cancer are lacking. METHODS: By using the Memorial Sloan-Kettering Testis Cancer database, the authors identified 255 patients who underwent primary retroperitoneal lymph node dissection (RPLND) for nonseminomatous germ cell tumors (NSGCTs) between 1999 and 2008. Features that were associated with lymph node counts, positive lymph nodes, the number of positive lymph nodes, and the risk of positive contralateral lymph nodes were evaluated with regression models. RESULTS: The median (interquartile range [IQR]) total lymph node count was 38 lymph nodes (IQR, 27-53 total lymph nodes), and it was 48 (IQR, 34-61 total lymph nodes) during the most recent 5 years. Features that were associated with higher lymph node count on multivariate analysis included high-volume surgeon (P = .034), clinical stage (P = .036), and more recent year of surgery (P < .001); whereas pathologist was not associated significantly with lymph node count (P = .3). Clinical stage (P < .001) and total lymph node count (P = .045) were associated significantly with finding positive lymph nodes on multivariate analysis. The probability of finding positive lymph nodes was 23%, 23%, 31%, and 48% if the total lymph node count was <21, 21 to 40, 41 to 60, and >60, respectively. With a median follow-up of 3 years, all patients remained alive, and 16 patients developed recurrent disease, although no patients developed recurrent disease in the paracaval, interaortocaval, para-aortic, or iliac regions. CONCLUSIONS: The current results suggested that >40 lymph nodes removed at RPLND improve the diagnostic efficacy of the operation. The authors believe that these results will be useful for future trials comparing RPLNDs, especially when assessing the adequacy of lymph node dissection.
BACKGROUND: Lymph node counts are a measure of quality assurance and are associated with prognosis for numerous malignancies. To date, investigations of lymph node counts in testis cancer are lacking. METHODS: By using the Memorial Sloan-Kettering Testis Cancer database, the authors identified 255 patients who underwent primary retroperitoneal lymph node dissection (RPLND) for nonseminomatous germ cell tumors (NSGCTs) between 1999 and 2008. Features that were associated with lymph node counts, positive lymph nodes, the number of positive lymph nodes, and the risk of positive contralateral lymph nodes were evaluated with regression models. RESULTS: The median (interquartile range [IQR]) total lymph node count was 38 lymph nodes (IQR, 27-53 total lymph nodes), and it was 48 (IQR, 34-61 total lymph nodes) during the most recent 5 years. Features that were associated with higher lymph node count on multivariate analysis included high-volume surgeon (P = .034), clinical stage (P = .036), and more recent year of surgery (P < .001); whereas pathologist was not associated significantly with lymph node count (P = .3). Clinical stage (P < .001) and total lymph node count (P = .045) were associated significantly with finding positive lymph nodes on multivariate analysis. The probability of finding positive lymph nodes was 23%, 23%, 31%, and 48% if the total lymph node count was <21, 21 to 40, 41 to 60, and >60, respectively. With a median follow-up of 3 years, all patients remained alive, and 16 patients developed recurrent disease, although no patients developed recurrent disease in the paracaval, interaortocaval, para-aortic, or iliac regions. CONCLUSIONS: The current results suggested that >40 lymph nodes removed at RPLND improve the diagnostic efficacy of the operation. The authors believe that these results will be useful for future trials comparing RPLNDs, especially when assessing the adequacy of lymph node dissection.
Authors: Wendy A Woodward; Vincent Vinh-Hung; Naoto T Ueno; Yee Chung Cheng; Melanie Royce; Patricia Tai; Georges Vlastos; Anne Marie Wallace; Gabriel N Hortobagyi; Yago Nieto Journal: J Clin Oncol Date: 2006-06-20 Impact factor: 44.544
Authors: Andrew J Stephenson; George J Bosl; Dean F Bajorin; Jason Stasi; Robert J Motzer; Joel Sheinfeld Journal: J Urol Date: 2005-08 Impact factor: 7.450
Authors: Andrew J Stephenson; George J Bosl; Robert J Motzer; Michael W Kattan; Jason Stasi; Dean F Bajorin; Joel Sheinfeld Journal: J Clin Oncol Date: 2005-04-20 Impact factor: 44.544
Authors: James M McKiernan; Robert J Motzer; Dean F Bajorin; Jennifer Bacik; George J Bosl; Joel Sheinfeld Journal: Urology Date: 2003-10 Impact factor: 2.649
Authors: Hege S Haugnes; Nina Aass; Sophie D Fosså; Olav Dahl; Marianne Brydøy; Ulf Aasebø; Tom Wilsgaard; Roy M Bremnes Journal: J Clin Oncol Date: 2009-05-04 Impact factor: 44.544
Authors: R Houston Thompson; Brett S Carver; George J Bosl; Dean Bajorin; Robert Motzer; Darren R Feldman; Victor E Reuter; Joel Sheinfeld Journal: Urology Date: 2010-12-15 Impact factor: 2.649
Authors: R Houston Thompson; Brett S Carver; George J Bosl; Dean Bajorin; Robert Motzer; Darren Feldman; Victor E Reuter; Joel Sheinfeld Journal: Urology Date: 2011-12-14 Impact factor: 2.649
Authors: Nicholas R Rocco; Sean P Stroup; Haidar M Abdul-Muhsin; Michael T Marshall; Michael G Santomauro; Matthew S Christman; James O L'Esperance; Erik P Castle Journal: World J Urol Date: 2019-09-09 Impact factor: 4.226
Authors: Christian D Fankhauser; Luca Afferi; Sean P Stroup; Nicholas R Rocco; Kathleen Olson; Aditya Bagrodia; Fady Baky; Walter Cazzaniga; Erik Mayer; David Nicol; Ekrem Islamoglu; Stephane de Vergie; Ragheed Saoud; Scott E Eggener; Sebastiano Nazzani; Nicola Nicolai; Lee Hugar; Wade J Sexton; Deliu-Victor Matei; Ottavio De Cobelli; Joseph Cheaib; Phillip M Pierorazio; James Porter; Thomas Hermanns; Robert J Hamilton; Andreas Hiester; Peter Albers; Noel Clarke; Agostino Mattei Journal: World J Urol Date: 2022-03-13 Impact factor: 4.226